Skip to content
2000
Volume 21, Issue 2
  • ISSN: 1381-6128
  • E-ISSN: 1873-4286

Abstract

Safety is usually a secondary endpoint in clinical trials, and most observational studies on predictors focus on response, not toxicity. Research is clearly biased towards efficacy rather than safety, probably because of the difficulty in measuring toxicity arising from lack of standardization, low statistical power, missing data, misinterpretation, and confounding variables. An extensive search revealed very few studies on toxicity markers for the drugs used to treat rheumatoid arthritis. The literature contains many studies on predictors of the safety of methotrexate. Most analyze genetic markers, which are difficult to apply in daily practice. We found few studies on markers of toxicity for biologics. As many adverse events are related to patient characteristics, we recommend that clinicians understand the risk factors for the most common adverse events, especially infections and cancer, and manage risk on an individual basis. Moreover, patient involvement in monitoring safety is crucial.

Loading

Article metrics loading...

/content/journals/cpd/10.2174/1381612820666140825124352
2015-01-01
2025-05-10
Loading full text...

Full text loading...

/content/journals/cpd/10.2174/1381612820666140825124352
Loading

  • Article Type:
    Research Article
Keyword(s): adverse effects; Rheumatoid arthritis; safety; toxicity
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test